A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

Inclusion Criteria: * • Have provided written informed consent prior to screening procedures (i.e. participants must be literate). * Healthy adult male or non-pregnant, non-lactating female, ages 18 to 55 (inclusive) at the time of screening * Free of clinically significant health problems, as determined by pertinent medical history, clinical examination and blood tests at screening * Available, able, and willing to participate for all study visits and procedures * Negative pregnancy-test for female volunteers * Females, of non-childbearing potential who are post-menopausal (i.e. ≥ one year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy) * Females, of childbearing potential, who are willing to use effective methods of contraception for 14 days before vaccination and 30 days after vaccination. * Males who are willing to use effective contraception following vaccination for a period of one week. * Be willing to minimize blood and body fluid exposure of others for 5 days after vaccination Exclusion Criteria: * • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions. * Known allergy to the components of the BPSC1001 vaccine product * Unable or unwilling to stay in the study area for the period of the study and comply with study procedures. * Ongoing participation in another clinical trial * Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines) * Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test * Any serologic evidence of hepatitis B SAg or HIV infection. * Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes * Have an active malignancy or history of metastatic or hematologic malignancy * Suspected or known alcohol and/or illicit drug abuse within the past 5 years * Moderate or severe illness and/or fever \>38°C within 2 weeks prior to vaccination * Pregnant or lactating woman or a woman who intends to become pregnant within 30 days following vaccination. * Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period * Administration of chronic (defined as more than 14 days) immunosuppressant's or other immune modifying drugs within 6 months of study entry * Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study